Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.

Inclusion Criteria: * Histological or clinical diagnosis of cirrhosis. * HCV infection confirmed on a positive test for anti-HCV antibody and HCV RNA detectable in serum by Polymerase Chain Reaction. * Patients who were non-responders to previous treatment with pegylated interferon and ribavirin or naïve patients with decompensated cirrhosis (Child-Pugh score ≥ 7) who had contraindicated the antiviral treatment. * Presence of compensated or decompensated (Stage A, B or C according to the Child-Pugh Classification). * Absence of clinical and ultrasonographic evidence of liver cancer, with α-fetoprotein levels ≤ 200 ng/ml. Exclusion Criteria: * Age less than 18 or greater than 70 years. * Presence of uncontrollable clinical or biochemical complications related to severe liver failure (hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding, serum bilirubin level greater than 5 mg/dL, international normalized ratio greater than 2.5). * Active alcoholism. * Serum creatinine greater than 2 mg/dL. * Hepatocellular carcinoma. * Refusal to participate in the study. * Concomitant disease with reduced life expectancy. * Severe psychiatric conditions. * Co-infection with hepatitis A or B or HIV. * Drug dependence. * Pregnancy.